Literature DB >> 27202347

Impact of Brain Metastases on Quality of Life and Estimated Life Expectancy in Patients with Advanced Non-Small Cell Lung Cancer.

A Roughley1, E Damonte2, G Taylor-Stokes1, A Rider1, V C Munk2.   

Abstract

Entities:  

Year:  2014        PMID： 27202347     DOI： 10.1016/j.jval.2014.08.2364

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  4 in total

1.  Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma.

Authors:  Changhui Li; Bo Zhang; Jindong Guo; Fang Hu; Wei Nie; Xiaoxuan Zheng; Lixin Wang; Yuqing Lou; Yinchen Shen; Baohui Han; Xueyan Zhang
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

2.  Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment.

Authors:  Lizza E L Hendriks; Deepa S Subramaniam; Anne-Marie C Dingemans
Journal:  Front Oncol       Date:  2018-11-06       Impact factor: 6.244

Review 3.  Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Authors:  Janna Josephus Anna Oda Schoenmaekers; Marthe Sentijna Paats; Anne-Marie Clasina Dingemans; Lizza Elisabeth Lucia Hendriks
Journal:  Transl Lung Cancer Res       Date:  2020-12

4.  Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC.

Authors:  Simon A Keek; Esma Kayan; Avishek Chatterjee; José S A Belderbos; Gerben Bootsma; Ben van den Borne; Anne-Marie C Dingemans; Hester A Gietema; Harry J M Groen; Judith Herder; Cordula Pitz; John Praag; Dirk De Ruysscher; Janna Schoenmaekers; Hans J M Smit; Jos Stigt; Marcel Westenend; Haiyan Zeng; Henry C Woodruff; Philippe Lambin; Lizza Hendriks
Journal:  Ther Adv Med Oncol       Date:  2022-08-22       Impact factor: 5.485
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.